Mövenpick Hotel Frankfurt City  
Den Haager Straße 5 - 60327 Frankfurt am Main - Germany  
Frankfurt, September 19th 2014

13.00/15.10 JOINT MEETING  
GCA attendees & ENGOT Translational Research Group

13.00/13.10 WELCOME  
Prof. Éric Pujade-Lauraine, Hôpital Hôtel-Dieu, Paris (France)

13.10/15.10 WORKSHOP SESSION I (5 TABLES): THE FUTURE OF HOMOLOGOUS RECOMBINATION DEFICIENCY IN OVARIAN CANCER  
At each table, pre-planned TR representatives present and discuss what would be the best methods to detect HRD and next anti-PARP trials. Summary and discussions at the end

FACILITATORS  
Prof. Sandro Pignata, Naples (Italy) & Prof. Jonathan Ledermann, London (United Kingdom)  
Prof. Christian Marth, Innsbruck (Austria), Prof. Bradley J. Monk, Phoenix (USA) & Prof. Antonio Casado, Madrid (Spain)  
Prof. Antonio González, Madrid (Spain), Prof. Michael Birrer, Boston (USA) & Prof. Mansoor Raza Mirza, Copenhagen (Denmark)  
Prof. Philipp Harter, Essen (Germany)

15.10/15.30 COFFEE

15.30/18.30 GCA ATTENDEES: TRIALS IN SURGERY

15.30/16.30 WORKSHOP II (4 TABLES) WHAT ARE THE ISSUES FOR SURGICAL TRIALS  
At each table, pre-planned young trialist representatives present and discuss the surgical trial issues: How to select centres? Hurdles? Open questions? Endpoints? Toxicity score and QoL questionnaires?. Summary and general discussions at the end

FACILITATORS  
Prof. Sandro Pignata, Naples (Italy), Prof. Jacobus Pfisterer, Kid (Germany) & Prof. Jonathan Ledermann, London (United Kingdom)  
Prof. Christian Marth, Innsbruck (Austria), Prof. Bradley J. Monk, Phoenix (USA) & Prof. Antonio Casado, Madrid (Spain)  
Prof. Antonio González, Madrid (Spain), Prof. Michael Birrer, Boston (USA) & Prof. Mansoor Raza Mirza, Copenhagen (Denmark)  
Prof. Philipp Harter, Essen (Germany)
16.30/18.30  SHARING THE EXPERIENCE OF SURGICAL TRIALS.
FUNDING OPTIONS, LEGAL ASPECT AND INSURANCE HURDLES, HOW TO SELECT CENTERS FOR SURGICAL TRIALS. WHAT ARE THE OPEN QUESTIONS IN FIRST-LINE OC?
Prof. Jacobus Pfisterer, Kiel (Germany) & Prof. Philipp Harter, Essen (Germany)

WHAT ARE THE ENDPOINTS? HOW TO ASSESS SAFETY/MORBIDITY OF SURGERY? DO WE HAVE THE RIGHT QUESTIONNAIRES FOR QOL? WHAT ARE THE OPEN QUESTIONS IN RELAPSE OC?
Prof. Jacobus Pfisterer, Kiel (Germany) & Prof. Philipp Harter, Essen (Germany)

Frankfurt, September 20th 2014

08.30/12.30  JOINT MEETING
GCA attendees & ENGOT Translational Research Group & ENGOT Phase I/II Group

08.30/09.30  CLINICAL TRIAL: PITFALLS
08.30/09.00  WHY CLINICAL TRIALS FAIL?
Prof. Christian Marth, Innsbruck (Austria)
09.00/09.30  THE TRICKY DECISION TO ALLOW CROSS-OVER OR NOT IN A TRIAL
Prof. Brad Monk, Boston (USA)
Q&A session/discussion

09.30/10.00  COFFEE

10.00/11.00  GENOMIC SIGNATURES: APPEAL AND LIMITS
10.00/10.30  WHY SIGNATURES ARE THE BEST WAY TO IDENTIFY SUBGROUPS IN OC
Prof. Charlie Gourley, Edinburgh (Scotland)
10.30/11.00  WHY SIGNATURES MISS THE GOAL IN OC
Prof. Mike Birrer, Boston (USA)
Q&A session/discussion

11.00/12.00  HOW TO TARGET p53 IN OVARIAN CANCER?
11.00/11.30  INHIBITING THE GAIN-OF-FUNCTION OF MUTATED p53
Dr. Nicole Concin, Innsbruck (Austria)
11.30/12.00  REVERSING MUTATED p53 TO WILD TYPE
Prof. Sevilay Altintas, Edegem (Belgium)
Q&A session/discussion

12.15  CLOSURE
Prof. Éric Pujade-Lauraine, Hôpital Hôtel-Dieu, Paris (France)

Organising Secretariat:
Doctaforum
Medical Events Specialists
Tel.: +34 91 372 02 03
E-mail: gca@doctaforum.com

ENGOT l GCA Secretariat
Krakovska 1307/22
110 00 Prague
Czech Republic
gca@esgemail.org

This GCA initiative is possible thanks to a generous educational grant from Roche